Thousands of people in England with a type of chronic heart failure are eligible for a new treatment option following our final draft guidance that recommends finerenone for adults with chronic heart ...

intermittently scanned continuous glucose monitoring. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following ...

Evidence-based recommendation on teplizumab (Tzield) for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes ...

Recommended medicines for weight management and related NICE guidance are shown in table 1. This should be read alongside NHS England's interim commissioning guidance for TA1026. All medicines for ...

This guide sets out how to submit evidence to NICE as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and ...

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and ...

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...

There is a simple discount patient access scheme for nivolumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.

The autism spectrum quotient (AQ-10) tool is recommended for use with adults with possible autism who do not have a moderate or severe learning disability. This may help identify whether an individual ...

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based ...